Wayshine (Hangzhou) Biopharm Co., Ltd. (abbreviated as "Wayshine Biopharm"), founded in 2016, is a multinational biopharm group specializing in the independent research and development of innovative anti-tumor drugs. The Company is registered in Hangzhou, with its China headquarters located in Shanghai. It has subsidiaries including Shanghai Weidao and Hangzhou Weiruibao, and maintains overseas entities in Delaware, California, and Hong Kong, forming a globalized R&D and operational footprint spanning China and the United States.
The Company focuses on brain tumors and solid tumors, and has built a core technology platform enabling efficient penetration of therapeutics across the blood-brain barrier, establishing a comprehensive R&D system covering target discovery, target validation, compound design, and preclinical development. Its lead product, WSD0922, is a first-in-class blood-brain barrier-penetrating EGFR/EGFRvIII-targeted inhibitor for indications including non-small cell lung cancer and glioma. WSD0922 has obtained FDA IND clearance and is being evaluated in Phase I/II clinical trials in the United States in collaboration with Mayo Clinic. In China, the clinical trial in non-small cell lung cancer patients harboring the C797S resistance mutation after first-line treatment with third-generation EGFR inhibitors has progressed to Phase III and been granted Breakthrough Therapy Designation (BTD) by the NMPA. The Company has completed multiple rounds of financing from prominent USD-denominated funds, continuously accelerating the development and internationalization of its innovative therapeutics.
